X

Trial Profile

A phase I pharmacologic study of CYC116, an oral aurora kinase inhibitor, in patients with advanced solid tumors.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 28 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CYC 116 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

23 Oct 2009 Planned end date changed from 1 Mar 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov (NCT00560716).
23 Oct 2009 Planned end date changed from 1 Mar 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov (NCT00560716).
23 Oct 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov (NCT00560716).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com